News about Clinical Trials

TRANSFORM 2 Trial Shows Sirolimus-Coated Balloon Matches Drug-Eluting Stents

TRANSFORM 2 trial found Concept Medical’s MagicTouch sirolimus-coated balloon non-inferior to drug-eluting stents, demonstrating comparable 12-month outcomes in 1,842 patients with coronary artery disease.

Clinical Trials | 06/11/2026 | By News Bureau

START Partners with Italy's Regina Elena Cancer Institute to Expand Early-Phase Clinical Trials

The partnership will establish START’s Italian early-phase clinical trial site at Regina Elena National Cancer Institute in Rome, expanding access to investigational cancer therapies.

Clinical Trials | 06/11/2026 | By News Bureau

Merck Initiates Phase 3 ENHANCE-3 Trial of Ohtuvayre for COPD Exacerbation Prevention

Merck initiates the phase 3 ENHANCE-3 clinical trial to evaluate Ohtuvayre for preventing COPD exacerbations in adults receiving standard-of-care treatment.

Clinical Trials | 05/11/2026 | By News Bureau

Boehringer Ingelheim Starts Phase 3 COPD Trial of Verducatib

Boehringer Ingelheim has launched phase 3 AIRWARD trial to assess verducatib’s safety and efficacy in adults with symptomatic COPD.

Clinical Trials | 02/11/2026 | By News Bureau |  113

Sobi Reports Positive Phase 3 Results for Pozdeutinurad in Gout

Sobi reports positive Phase 3 REDUCE-2 results for investigational gout treatment pozdeutinurad, demonstrating sustained serum urate reduction over 12 months.

Clinical Trials | 30/10/2026 | By News Bureau

Vanda Pharma's NEREUS Shows Positive Results in GLP-1 Vomiting Study

Vanda Pharmaceuticals has reported positive NEREUS Study 3601 results, showing reduced semaglutide-induced vomiting, including frequent, multi-day and extreme episodes.

Clinical Trials | 30/10/2026 | By News Bureau

Eli Lilly Reports Phase 3 Results for Retatrutide Against Ozempic in Type 2 Diabetes

Eli Lilly has reported positive Phase 3 results for investigational retatrutide, which demonstrated greater reductions in A1C and body weight than Ozempic 2 mg in adults with type 2 diabetes. Retatrutide is not approved for human use.

Clinical Trials | 29/10/2026 | By News Bureau

Pfizer's ELREXFIO Meets Phase 3 Endpoint in Myeloma

Pfizer’s ELREXFIO has outperformed standard regimens and meets primary endpoint in phase 3 study in Relapsed or Refractory Multiple Myeloma (RRMM).

Clinical Trials | 28/10/2026 | By News Bureau

Roche's Sefaxersen Cuts Proteinuria in Phase 3 IgAN Trial

Roche has announced new phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN).

Clinical Trials | 27/10/2026 | By News Bureau |  103

AstraZeneca's Sonesitatug Vedotin Cuts Death Risk by 42 Percent

AstraZeneca’s sonesitatug vedotin cuts death risk by 42 percent in advanced CLDN18.2-positive gastric cancer, with a 53 percent reduction in later-line treatment.

Clinical Trials | 26/10/2026 | By News Bureau